Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xavier Paoletti

Showing results (111-120 of 145) with videos related to

Pageof 15
Sort By:
European Journal of Cancer (Oxford, England : 1990)|January 29, 2013
Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis, Koji Oba, Xavier Paoletti, et al.
Plos One|November 7, 2014
Predictive gene signature of response to the anti-TweakR mAb PDL192 in patient-derived breast cancer xenograftsLudmilla de Plater, Anne Vincent-Salomon, Frédérique Berger, et al.
Bulletin Du Cancer|January 23, 2015
[The role of the expansion cohort in phase I trials in oncology: guidelines of the phase I HUB]Monia Ezzalfani, Audrey Dugué, Caroline Mollevi, et al.
Cancers|March 29, 2023
CA-125 Early Dynamics to Predict Overall Survival in Women with Newly Diagnosed Advanced Ovarian Cancer Based on Meta-Analysis DataEleni Karamouza, Rosalind M Glasspool, Caroline Kelly, et al.
Future Oncology (London, England)|May 5, 2025
DOMENICA: dostarlimab versus chemotherapy alone in first-line MMR-deficient advanced endometrial cancer patientsFrançois Cherifi, Isabelle Ray-Coquard, Maria Jesus Rubio, et al.
Targeted Oncology|November 20, 2012
Designs and challenges for personalized medicine studies in oncology: focus on the SHIVA trialChristophe Le Tourneau, Maud Kamal, Olivier Trédan, et al.
Journal of the National Cancer Institute|October 11, 2013
Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysisKoji Oba, Xavier Paoletti, Steven Alberts, et al.
Neuro-Oncology|October 27, 2010
Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumorsBirgit Geoerger, Darren Hargrave, Fabienne Thomas, et al.
European Journal of Cancer (Oxford, England : 1990)|August 5, 2023
Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysisPauline Corbaux, Benoit You, Rosalind M Glasspool, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 19, 2025
Identifying high-risk relapse in early-stage I to II ovarian cancer using the CA125 ELIMination rate constant K (KELIM) score: a Gynecologic Cancer InterGroup individual patient-data meta-analysisPauline Corbaux, Benoit You, Tatsuo Kagimura, et al.
Pageof 15

Showing results (111-120 of 145) with videos related to

Sort By:
Pageof 15
European Journal of Cancer (Oxford, England : 1990)|January 29, 2013
Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis, Koji Oba, Xavier Paoletti, et al.
Plos One|November 7, 2014
Predictive gene signature of response to the anti-TweakR mAb PDL192 in patient-derived breast cancer xenograftsLudmilla de Plater, Anne Vincent-Salomon, Frédérique Berger, et al.
Bulletin Du Cancer|January 23, 2015
[The role of the expansion cohort in phase I trials in oncology: guidelines of the phase I HUB]Monia Ezzalfani, Audrey Dugué, Caroline Mollevi, et al.
Cancers|March 29, 2023
CA-125 Early Dynamics to Predict Overall Survival in Women with Newly Diagnosed Advanced Ovarian Cancer Based on Meta-Analysis DataEleni Karamouza, Rosalind M Glasspool, Caroline Kelly, et al.
Future Oncology (London, England)|May 5, 2025
DOMENICA: dostarlimab versus chemotherapy alone in first-line MMR-deficient advanced endometrial cancer patientsFrançois Cherifi, Isabelle Ray-Coquard, Maria Jesus Rubio, et al.
Targeted Oncology|November 20, 2012
Designs and challenges for personalized medicine studies in oncology: focus on the SHIVA trialChristophe Le Tourneau, Maud Kamal, Olivier Trédan, et al.
Journal of the National Cancer Institute|October 11, 2013
Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysisKoji Oba, Xavier Paoletti, Steven Alberts, et al.
Neuro-Oncology|October 27, 2010
Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumorsBirgit Geoerger, Darren Hargrave, Fabienne Thomas, et al.
European Journal of Cancer (Oxford, England : 1990)|August 5, 2023
Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysisPauline Corbaux, Benoit You, Rosalind M Glasspool, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 19, 2025
Identifying high-risk relapse in early-stage I to II ovarian cancer using the CA125 ELIMination rate constant K (KELIM) score: a Gynecologic Cancer InterGroup individual patient-data meta-analysisPauline Corbaux, Benoit You, Tatsuo Kagimura, et al.
Pageof 15